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SUMMARY 
Lymphoma is one of the most common neoplastic disorders in domestic cats. The disease is a challenge 
for clinicians to diagnose and prognosticate due to many different possible anatomic locations and 
various, unspecific clinical signs. The personal value of cats as pets is increasing for cat owners, 
demanding more advanced veterinary care for their cats. Lymphoma is a cancer which is increasing in 
cats, thus giving yet another reason for improving possibilities in handling feline lymphoma patients. A 
tumor biomarker to help detect early stages of lymphoma, to help differentiate lymphoma from other 
diseases with similar clinical signs, to monitor treatment and as an aid to prognosticate would be of great 
use in feline oncology. 
Tumor biomarkers are widely used in human medicine for these purposes as well in some extent in 
canine oncology. Thymidine kinase is an enzyme involved in the DNA-synthesis, and levels of this 
enzyme in sera is correlated to cell proliferation, i.e. serum thymidine kinase (sTK) levels are higher in 
cancer patients due to the rapid cell division rate in cancer cells.  
The aim of this study was to examine the serum thymidine kinase 1 (sTK1) activity levels in healthy 
cats to be able to calculate a reference value, and to see if there was an individual variation in sTK1 
activity levels depending on age or gender. The study group consisted of 35 healthy cats with various 
age, gender and breed. To be included in the study the cats had to be evaluated as clinically healthy on 
clinical examination, and to be healthy on blood screening (hematology and serum biochemistry profile).  
The study resulted in a reference value of <0.933 pmol/min/mL, and showed that there was no individual 
variation depending on age or gender. The results from this study is a good starting point for future 
studies as it is a consistent group of healthy cats to use as comparison for sick cats. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 SAMMANFATTNING 
Lymfom är en av de vanligaste neoplastiska sjukdomarna hos domesticerade katter. Sjukdomen är en 
utmaning för kliniker att diagnostisera och prognosticera på grund av många olika anatomiska 
variationer och ospecifika kliniska symptom. Det personliga värdet för katter som husdjur ökar hos 
kattägare som då kräver en mer avancerad veterinärvård, vilket bidrar till en önskan om att förbättra 
diagnostiken och möjligheterna i vårdandet av dessa katter. En biomarkör för att kunna upptäcka 
sjukdomen i ett tidigare stadie, för att lättare differentiera lymfom från andra sjukdomar med liknande 
kliniska symptom, för att kontrollera behandling och som en prognostisk faktor skulle vara till stor nytta 
inom veterinärmedicinen. 
Biomarkörer används i hög utsträckning inom humanmedicinen för dessa syften och även till viss del 
inom veterinärmedicinen, då framförallt på hundar. Tymidinkinas är ett enzym som är involverat i DNA-
syntesen, och nivåerna av enzymet i serum är korrelerade till cellproliferation, alltså är 
serumtymidinkinas (sTK)-nivåer högre hos cancerpatienter på grund av den snabba celldelningen hos 
cancerceller. 
Syftet med den här studien var att undersöka sTK1-aktivitetsnivåer hos friska katter för att beräkna att 
referensvärde, samt undersöka om det förelåg en individvariation beroende på kön eller ålder. 
Studiegruppen bestod av 35 friska katter av varierande ålder, ras och kön. För att inkluderas i studien 
behövde katten klassas som frisk vid klinisk undersökning och på blodprover (hematologi och flera olika 
kemianalyser). 
Resultaten av studien ledde till ett referensvärde på <0,933 pmol/min/mL och visade att det inte finns 
någon individvariation beroende på kön eller ålder. Resultaten utgör en bra utgångspunkt för framtida 
studier inom samma ämne. 
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INTRODUCTION 
Lymphoma is one of the most common neoplastic disorders in the domestic cat, with an estimated 
incidence of 200 per 100,000 cats at risk, making it the most common malignancy in this species. It is a 
form of cancer that originates from lymphoreticular cells, thus affecting lymphoid tissues. Feline 
lymphoma is often disguised behind many different clinical signs and can be found almost anywhere in 
the body, making it a challenge for clinicians to diagnose and to obtain a prognosis for affected patients. 
Due to the great variation of feline lymphoma, it is difficult to generalize clinical signs, signalment and 
prognosis (Withrow et al., 2013). 
The etiology of feline lymphoma is of either non-viral or retrovirus-associated origin, with the non-viral 
origin being most common to date, unlike before the 1980’s when the retroviral lymphomas were more 
common. The retroviruses that increase the risk of feline lymphoma are FeLV and FIV. These viruses 
still increase the risk of lymphoma in infected cats, but the number of infected cats have decreased due 
to improved diagnostics and introduction of the FeLV vaccine on the market (Louwerens et al., 2005). 
As earlier mentioned there is a great variation in clinical signs, mostly because of multiple anatomic 
locations, thus making diagnostics and prognostication challenging for the clinician. Diagnosis is 
generally achieved via cytology or histopathology and there are multiple chemotherapeutic controls used 
in the disease management. The factors used today for obtaining a prognosis are clinical response to 
treatment, location of the lymphoma and clinical staging (which is difficult to do in feline lymphoma 
patients). In canine patients with lymphoma there are more prognostic factors to use such as 
immunophenotyping, tumor markers and better possibilities for clinical staging. Unfortunately, these 
alternatives are not equally usable for feline lymphoma patients (Nelson & Couto, 2009). 
Since feline lymphoma is such a common malignancy and that there is no optimal way to prognosticate 
it, a biomarker would be of great use, both as a prognostic indicator as well as for diagnostics. Thymidine 
kinase is an enzyme involved in DNA-replication and therefor exists in higher levels in rapidly dividing 
cells. This has been used in human and canine oncology where this enzyme is used as a serum biomarker. 
A few studies have been made to try to find a way to apply this in feline medicine as well. One study by 
Taylor et al. (2013) found a serum thymidine kinase 1 (sTK1) activity reference interval of <5.5 U/l and 
that cats with lymphoma had significantly higher sTK 1 activity levels than healthy cats.  
Aim of the study 
In this study, serum thymidine kinase 1 (sTK1) levels were measured in healthy cats by radiochemical 
assay using the DE-81 filter paper technique. The aim of the study was to: 
 Obtain a reference interval/value for sTK1 activity in healthy cats. 
 Examine if there is an individual variation of sTK1 activity in healthy cats, e.g. in gender or 
age. 
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LITERATURE REVIEW 
Feline lymphoma 
Lymphoma (i.e., malignant lymphoma, lymphosarcoma) is one of the most common neoplastic 
disorders and the most common neoplasm of the hematopoietic system seen in cats, with an estimated 
incidence of 200 per 100,000 cats at risk. It is a form of neoplasm that origin from lymphoreticular cells, 
which means that the affected organs are those that consist of lymphoid tissues, such as lymph nodes 
and spleen, i.e. the cancer begins in the cells of the lymph system. There is also a form of lymphoma 
that origins from the bone marrow; lymphoid leukemia. Due to the anatomic distribution of the lymphoid 
system, lymphoma can be found almost anywhere in the body (Withrow et al., 2013). 
The anatomic variation of feline lymphoma makes it difficult to point out specific symptoms of the 
disease since the clinical findings correlate to the anatomic site of the neoplasm. It is also hard to state 
a typical signalment for cats with lymphoma due to the frequent occurrence of unspecific clinical signs 
and the often no apparent enlargement of peripheral lymph-nodes in contrary to what is common in 
canine lymphoma patients. Four anatomic forms of presentations are described in table 1 below; 
multicentric, mediastinal, alimentary and extra nodal, where the alimentary form is most common in 
cats (Nelson & Couto, 2009). 
Table 1. Different forms of lymphomas seen in cats 
Form of 
lymphoma 
Anatomic site Clinical presentation 
Multicentric Generalized lymphadenopathy with 
either hepatic, splenic or bone 
marrow involvement and sometimes 
a combination of these 
Often nonspecific symptoms such as weight 
loss, anorexia and lethargy. Owners may 
seek veterinary care only due to the 
discovery of subcutaneous masses, i.e., 
enlarged lymph-nodes 
Mediastinal Mediastinal lymphadenopathy, with 
or without bone marrow infiltration 
Dyspnea, coughing, regurgitation due to 
compression of the respiratory and upper 
digestive tract from enlarged mediastinal 
lymph-nodes. Some cats present with uni- or 
bilateral Horner´s syndrome 
Alimentary Solitary, diffuse or multifocal 
gastrointestinal tract infiltration with 
or without intraabdominal 
lymphadenopathy 
Vomiting, anorexia, diarrhea and weight 
loss 
Extra nodal May affect any organ or tissue, for 
example: renal, neural, 
nasopharyngeal, ocular 
Variable, depends on the location of the 
lymphoma 
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Etiology of feline lymphoma 
The etiology of feline lymphoma is often unknown, but it can be divided in to two basic types; those 
that are retrovirus-associated and those that are of non-viral origin. It is a recognized fact that retroviral 
infected cats have an increased risk of this cancer. FeLV (feline leukemia virus) increases the risk 62 
fold, FIV (feline immunodeficiency virus) increases the risk 6 fold whereas a simultaneous infection of 
both FeLV and FIV infection increases the risk 77 fold (Louwerens et al., 2005; Shelton et al., 1990).  
Non-retroviral-associated lymphoma 
Currently, the largest group is however the non-retroviral-associated lymphomas, which are lymphomas 
of B- or T-cell lineage that tend to be more organ specific and solitary, whereas FeLV-associated 
lymphomas often are of T-cell lineage and a generalized form, and FIV-associated lymphoma are more 
likely to be of B-cell linage (Louwerens et al., 2005). The underlying cause of the non-retroviral-
associated lymphomas is not fully understood. Bertone et al (2002) suggests that chronic cigarette smoke 
exposure may increase the risk of lymphoma in cats. Multiple studies imply a correlation between feline 
lymphoma and chronic inflammation, such as the possible linkage between inflammatory bowel disease 
and alimentary lymphoma (Carreras et al., 2003; Ragaini et al., 2003).  
Siamese cats appear to have a higher risk in developing lymphoma, which suggests a genetic 
predisposition as well (Dorn et al., 1967). Louwerens et al. (2005) describe a group of twelve cases of 
FeLV-neagtive Oriental Short-hair cats with lymphoma, where all the cats in this group had an early 
onset (2 years old) and a similar clinical presentation (mediastinal lymphoma). This, combined with the 
absence of a viral etiology in these cats suggests a genetic, heritable form of lymphoma in this breed. 
Lymphoma and FeLV 
Lymphoma is as stated the most common malignancy of domestic cats, and FeLV, feline leukemia virus, 
is a recognized etiology of the disease. A FeLV-infected cat increases its risk 60 times of getting 
lymphoma compared to a non-infected cat (Shelton et al., 1990). FeLV is a gammaretrovirus and is 
transmitted vertically and horizontally, infecting domestic cats around the world. 
FeLV infection was more common in cats from the 1950s through the 1970s. In 1973, the first diagnostic 
test and elimination regimen made its appearance on the market which in combination with the first 
commercial vaccine in 1986 resulted in a rapid decline in FeLV-infected cats. Before the control by test 
and vaccination of FeLV started, more than 70% of cats with lymphoma were infected and hence the 
most important form of lymphoma was the retrovirus-associated form (Louwerens et al., 2005). 
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Louwerens et al. (2005) found that even though the decrease in FeLV-associated lymphoma cases, 
lymphoma in cats is increasing. One explanation could be, according to the authors, that more clients 
may be considering treatment for their cats as well as the probable genetic lymphoma in young Siamese-
cats, and the possible link between chronic inflammation and intestinal lymphoma. The authors suggest 
that the connection between chronic inflammation and intestinal lymphoma could be a result of dietary 
changes in cats. 
Lymphoma and FIV 
FIV, feline immunodeficiency virus, is a lentivirus and is described as an animal model for HIV infection 
and acquired immunodeficiency syndrome (AIDS) in humans. The virus itself does not cause severe 
clinical signs but increases the risk of opportunistic infections and tumors. In experimentally infected 
cats, the infection has several stages; acute phase, asymptomatic phase and terminal phase. The last 
terminal phase, is sometimes referred to as “feline acquired immunodeficiency syndrome” (FAIDS) and 
it is here the clinical signs, for example neoplasia, is seen (Hartmann, 2011). 
As earlier mentioned, FIV infection increases the risk of lymphoma 6-fold and cats infected with FIV 
often have lymphoma. FIV is believed to play an indirect role in the development towards lymphoma, 
as it has immunosuppressive effects that dysregulates the immune system. The virus is only occasionally 
detected in tumor cells, also suggesting a direct role (Wang et al., 2001). The virus may increase the risk 
of cancer in the following ways; by decreasing tumor immunosurveillance mechanisms, may promote 
tumor development through the immunostimulatory effects of replicating in lymphocytes and/or may 
impair immunological control of FeLV infection and accelerate the proliferation of transformed 
lymphoid cells (Hartmann, 2011). 
FIV may also have a more direct role in the disease development since it is classified into the family 
retroviridae (same as FeLV) which is assumed to possess the potential for tumorigenesis (Endo et al., 
1997). Gabor et al. (2001) showed in a cohort study that the prevalence of FIV infection was 50% higher 
in cats with lymphoma compared to the FIV prevalence in the cat population without lymphomas, which 
also supports the theory of a more direct role in the pathogenesis of lymphoma. 
Diagnosis 
The diagnostic evaluation of a cat with suspected lymphoma should include a CBC with differential cell 
count, platelet count, a serum chemistry profile, urinalysis and FeLV/FIV screen. This will help to get 
an overall picture about the cat’s general health status as well as, in some cases, reveal tumor 
involvement in certain organs (Withrow et al., 2013). It can also help the clinician and the owner in the 
decision making whether to treat the patient or not. If the decision is to treat the patient, these parameters 
are a good baseline for further evaluation and also necessary for deciding what kind of treatment the 
patient will receive (Nelson & Couto, 2009). 
  
5 
 
A cytopathologic and/or histopathologic evaluation of lymph node or involved organ tissue is a must to 
establish a definitive diagnosis. This can be done via fine needle aspirate (FNA) or biopsy (surgical, 
endoscopic or needle-core). Nelson & Couto (2009) promotes a cytological evaluation by FNA rather 
than histopathological findings by biopsy due to the financial aspects of the method combined with the 
very low/non-existing morbidity compared to a biopsy which includes a higher cost for the owners as 
well as a greater risk for the patient. If needed, the test material can be further investigated by for 
example histochemical, immunohistochemical, flow cytometric analysis and molecular techniques 
(Withrow et al., 2013). 
It is also possible, and more and more common, to perform immunophentoyping of the lymphoma to 
determine B- versus T-cell origin of the tumor. This can be done by immunocytochemistry, 
immunohistochemistry, flow cytometry or PCR for clonality (Nelson & Couto, 2009). In dogs this can 
be of value for prognosis but unfortunately this is not the case in cats (Argyle et al., 2008). 
Clinical staging 
There are staging systems for cats (more commonly used in canine patients with lymphoma), but due to 
the different anatomic forms and the variation in feline lymphoma they are generally less helpful than 
in dogs (Withrow et al., 2013). One staging system is the one provided by the World Health Organization 
(WHO), a system based on TNM (tumor, node, metastasis) – a staging system used for neoplasms in 
humans, which is based on clinical and clinical pathologic information about the patient. All this is 
weighed together to obtain a prognosis, however this protocol cannot be used prognostically in cats 
according to the authors (Nelson & Couto, 2009). Nelson & Coutu (2009) thinks that there is no effective 
protocol for staging feline lymphoma to obtain a prognosis. 
According to Argyle et al. (2008) the response to treatment is the most important prognostic factor in 
cats with lymphoma. FeLV is a negative prognostic factor in cats with lymphoma (Nelson & Couto, 
2009). The prediction and prognosis of outcomes in cats with lymphoma is not possible to establish and 
generalize due to the great variation seen (Withrow et al., 2013). 
Treatment 
Argyle et al. (2008) list 3 different therapeutic regimes; no treatment, single-agent therapy and 
combination chemotherapy. An example of single-agent therapy is prednisolone which is mostly seen 
as a palliative care and is often used in GI lymphoma. The best treatment of choice when assessing feline 
lymphoma is chemotherapy. There are two main chemotherapeutic approaches in feline lymphoma: 
induction chemotherapy followed by maintenance which is a less aggressive COP (cyclophosphamide, 
vincristine and prednisone)- based protocol, or a more aggressive chemotherapy for a set period of time 
and with no maintenance chemotherapy after that. In this more aggressive chemotherapy, a CHOP 
(cyclophosphamide, doxorubicin, vincristine and prednisone)-based protocol is used (Nelson & Couto, 
2009).  
Many oncologists choose the COP protocol for cats since there is no strong evidence that doxorubicin 
provide any clinical benefit for cats and can also be nephrotoxic for some feline patients (Argyle et al., 
2008). The COP protocol has some of the highest rates of complete remission (CR, i.e, disappearance 
of all measurable tumors) and the longest survival times in the treatment of feline lymphoma with a 
minimal treatment-related toxicity (Teske et al., 2002). The same study also showed that response to 
treatment with the COP protocol had a great prognostic potential. If the treated cat achieved CR it had 
a much longer survival time than those that did not. 
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The commonly used COP protocol is most often administrated intravenously (IV). This can however be 
a problem for some cats who are unwilling to be restrained and injected IV, causing stress and discomfort 
for the cat. Sedation is a possible solution but adds costs to an already expensive treatment. This led 
Teske et al. (2014) to investigate intraperitoneal (IP) administration of the COP protocol. The authors 
implied that this route of administration reduced stress for the patient and improved safety for the 
administrator. The results were that IP administration is a safe and effective route for the administration 
of COP protocol, thus adding another option for treatment administration (Teske et al., 2014). 
Combination protocols tend to be more effective than single-agent ones. According to Nelson & Couto 
(2009) cats who are treated with multiple-agent chemotherapy protocols are expected to live 6 to 9 
months while the approximate survival time for untreated cats is 4 to 8 weeks. The same authors opinion 
is that cats tolerate chemotherapy for lymphoma quite well and that most owners are happy with the 
choice to treat their cat, and most cats get an improvement in quality of life after therapy. 
Biomarkers 
In human medicine the use of tumor biomarkers is considered standard practice to provide the clinician 
with diagnostic and prognostic information. This is also examined in veterinary medicine, most of all 
on canine patients where thymidine kinase is one biomarker that is used in the clinic (Taylor et al., 
2013). 
Diagnostic markers 
There are often specific characteristics of a patient or a disease, such as clinical, molecular or pathologic 
features that can be associated with a specific disease. This is used as a clinical tool to help the clinician 
to obtain the diagnosis of a patient. These markers are not necessarily associated with a clinical outcome 
or response to treatment (Webster et al., 2011). 
Prognostic and predicitive markers 
These are markers that are associated with a clinical outcome or a treatment outcome, and are used to 
identify the likely progression of a patient´s disease and to determinate modalities that are the most 
appropriate and efficacious for that specific patient (Webster et al., 2011). 
Tumor biomarkers 
Tumor biomarkers are substances that are produced by cancer cells, or by other cells in the body as a 
response to cancer. Some tumor markers are made by normal cells as well as cancer cells, but are 
produced much faster in cancer cells due to their rapid cell division (Holland et al., 2003). 
In human medicine, different tumor markers are used to evaluate tumor progression, response to therapy 
and also as diagnostic tools. An elevated level of a tumor biomarker is however not enough to diagnose 
cancer, but is combined with other tests, such as biopsies of affected tissues. The markers can be found 
in blood, urine, stool, tumor tissue, or other tissues or bodily fluids in some cases. PSA, CD20 and AFP 
are examples of different tumor markers used in human medicine (Holland et al., 2003; Sharif et al., 
2012).  
An important aspect when developing a tumor marker test is to find the true positive cases. This is partly 
achieved by setting a high bar for the reference value. This will however increase the risk of more cancer 
cases being missed, thus stating the fact that a biomarker should be used as a tool for the clinician, and 
not as the final decision maker. It may also be used as a monitoring control by following the values in a 
patient with diagnosed and treated cancer (Taylor et al., 2013). 
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Thymidine kinase 
Thymidine kinase (TK) is a cellular enzyme that convert deoxythymidine to deoxythymidine 
monophosphate as part of the one-step salvage pathway of pyrimidine synthesis, thus have a function in 
DNA synthesis, leading to higher levels of the enzyme in rapidly proliferating cells. This is used as a 
tumor marker in humans and dogs and especially as a prognostic indicator for lymphoma (Taylor et al., 
2013). Figure 1 illustrates the role of TK in the salvage pathway. 
Figure 1. The role of TK in the salvage pathway of the pyrimidine 
synthesis. From von Euler et al. (2004) and published with permission 
from the authors. 
There are two forms/isoenzymes of TK; TK1 (cystolic form) and TK2 
(mitochondrial form). TK2 is expressed in all cells independent of stage 
in the cell cycle. TK1 is however cell cycle-regulated and is highly 
associated with cellular proliferation. In normal cells TK1 activity is 
present only for a short period of time in the early S-phase of cell division, 
but is often much higher in abnormal cells. An extracellularly increase of 
TK1 activity is correlated to the rate of cell division which is particularly 
high in hematopoietic malignancies such as lymphoma (Taylor et al., 
2013). As excessive and uncontrolled, rapid cell proliferation is one of 
the hallmarks of cancer, and the fact that TK1 expression is correlated to 
the overall level of proliferation being a S phase-specific protein, it has 
come to be of great value, most of all in human oncology (Bello, 1974).  
A study performed by Taylor et al. (2013) showed that cats with lymphoma had a significantly higher 
sTK1 activity than clinically healthy cats, thus suggesting that sTK1 activity is a potential biomarker for 
feline lymphoma. The use of sTK1 activity as a tool in diagnosing feline lymphoma would be of great 
use due to the various clinical signs in cats with lymphoma as stated before. 
MATERIAL AND METHODS 
Healthy cats 
Blood samples (sera and EDTA) from 35 healthy cats were collected at the University Animal Hospital, 
Swedish University of Agricultural Sciences, Uppsala. The selection of cats was not limited by age, 
gender or breed. All cats included in this study were classified as healthy after being clinically examined 
by a veterinary student and after blood tests were run at The Clinical Pathology Laboratory, at the 
University Animal Hospital, Swedish University of Agricultural Sciences, Uppsala. The blood tests 
included hematological profile and serum biochemistry profile, more specifically CBC, ALT, albumin, 
ALP, SAA, bile acids, glucose, calcium, potassium, creatinine and total protein. To be included in the 
study the cat had to be classified as healthy clinically and on the blood tests. 
TK1 assay 
TK1 activity was measured by radiochemical assay using the DE-81 filter paper technique. The reaction 
mixture used contained Tris-HCl pH 7.6, 10 mM; DTT, 2mM; MgCl2, 5 mM; NaF, 5mM; ATP, 5mM; 
M [3H]-dThd and 10 L serum in a final volume of 40 L. The reaction mixture was incubated for 1 
h at 37 C. Two aliquots of the reaction mixture were applied to the DE-81 filter paper discs and dried. 
The filters were then washed twice with 1 mM ammonium formate for 5 minutes and the products were 
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eluted for 45 minutes in 0.1 M HCl and 0.2 M KCl. Finally, the radioactivity was measured by  
scintillation liquid counting and the activity was expressed as pmol/min/mL (Sharif et al., 2012). 
Statistical analysis 
To calculate a reference interval, the formula MeanSD was used. To examine if there was an individual 
variation in sTK1 activity levels (for example, does it matter if the cat is male or female), a scatter plot 
including age, gender and sTK1 activity was made. To compare sTK1 activity in males vs females and 
cats 1years old vs cats 2 years old, the Mann-Whitney U test were used. 
RESULTS 
sTK1 activity 
Sera from 35 clinically healthy cats was analyzed by radiochemical assay as described in Material and 
methods. The mean and median age of the study group were 4.7 and 3.5 years respectively. The youngest 
cat was 6 months old and the oldest was 16 years old. The group consisted of 16 females (11 spayed, 5 
entire) and 19 males (16 neutered, 3 entire), 8 pedigree cats and 27 non-pedigree cats. Figure 2 shows 
the sTK1 activity distribution. 
Figure 2. Serum TK1 activity distribution 
in healthy cat sera. N=35, Mean=0.503, 
Median=0.470, Cut-off 
value=Mean2SD=0.5030.211=(0.073-
)0.93 pmol/min/mL. 
 
 
 
 
 
A reference interval of 0.073-0.933 pmol/min/mL was calculated based on the mean sTK1 activity of 
0.503 pmol/min/mL and a standard deviation of 0.211 pmol/min/mL. Below the mean and median 
values from different groups are shown in table 2. 
Table 2. Mean and median sTK1 activity for different groups 
 Mean sTK1 activity 
(pmol/min/mL) 
Median sTK1 activity 
(pmol/min/mL) 
Complete study group (n=35) 0.503 0.470 
Males (n=19) 0.486 0.470 
Females (n=16) 0.504 0.435 
Cats 1 years old (n=9) 0.596 0.490 
Cats  2 years old (n=26) 0.459 0.430 
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Individual variation in sTK1 activity 
Below, figure 3 shows the results in a scatter plot with sTK1 activity as a function of age. The plot 
implies that there seems to be no pattern, i.e. the sTK1 activity levels seems to not be affected by age. 
 
 
Figure 3. A scatter chart of the results. Y=TK1 activity, x=age. The blue series represent the females 
and the yellow series the males. 
sTK1 activity and gender 
The median sTK1 activity was 0.435 pmol/min/mL for females and 0.470 pmol/min/mL for males, and 
the mean sTK1 activity 0.504 pmol/min/mL and 0.486 pmol/min/mL respectively. By using the Mann-
Whitney U test to compare if there was a difference in sTK1 activity between genders, a p-value of 
0.920 was calculated, i.e. there was no significant difference in sTK1 activity between males and 
females. 
sTK1 activity and age 
To compare if there was a difference in sTK1 activity between ages, the study group was divided into 
two groups; 1 years old and 2 years old. The mean and median sTK1 activity for the young group 
was 0.596 pmol/min/mL and 0.490 pmol/min/mL. For the older cats the mean and median sTK1 activity 
was 0.459 pmol/min/mL and 0.430 pmol/min/mL. The Mann-Whitney U test was performed to calculate 
the difference between the groups. Due to a calculated p-value of 0.865, the result showed no significant 
difference in sTK1 activity between younger and older cats. 
DISCUSSION 
Tumor markers are widely used in human medicine and also in some extent in canine patients. These 
markers are used as a tool for clinicians to help diagnose, prognosticate and monitor their patients. Such 
a tool would be of great use for the clinicians facing feline lymphoma patients due to the challenge of 
diagnosing and prognosticate the disease in this species. Diagnosing different types of feline lymphoma, 
for example alimentary lymphoma, can be painful for the patient (biopsies from the GI-tract is often 
necessary) and costly for the cat owner. If there was a tumor marker to use, it could save time, pain and 
unnecessary suffering for the cat as well as money for the cat owner (von Euler & Eriksson, 2011). 
It can be hard to differentiate feline lymphoma (alimentary lymphoma in particular) from chronic 
enteropathies due to similar clinical signs. In 2017 a retrospective study on chronic enteropathies in cats 
was made. The study included 147 cats. 12% of the cats had lymphoma, and to be able to differentiate 
those, histopathological reviews of the intestines had to be performed. This means that 18 cats had to go 
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through, for them, an unnecessary surgical procedure (Mitze et al., 2017). If there was a tumor marker 
for aiding the diagnostic process of feline lymphoma, these cats may have eluded unnecessary suffering. 
Thymidine kinase is one tumor marker that is frequently used in human oncology and provides accurate 
information about prognosis, for monitoring outcome of tumor therapy and for early discovery of cancer 
(He et al., 2010). In canine lymphoma patients serum thymidine kinase has been evaluated with good 
results and is in some extent used in the clinic (Jagarlamudi et al., 2014). Hopefully, this is a future in 
feline oncology as well. Taylor et al. (2013) performed a study where they analyzed sTK1 activity in 
cats to set a starting point for this cause. Their study implicated that there is a significant difference 
between lymphoma cats and healthy cats, i.e. cats with lymphoma have a higher sTK1 activity. 
The main object of this study was to examine the sTK1 activity in healthy cats, and to calculate a 
reference interval for the study group from the collected data. One aim was also to study if there was an 
individual variation in sTK1 activity levels depending on age or gender. The reference interval 
calculated was 0.073-0.933 pmol/min/mL, with the higher value of 0.933 pmol/min/mL being the cut 
off value. This implies that a healthy cat should have <0.933 pmol/min/mL sTK1 activity and higher 
values would give a suspicion of disease. However, no lymphoma cases or other clinical cases were 
included in this study for comparison. The results also showed that there were no significant difference 
in sTK1 activity depending on gender or age. 
A master thesis from 2013 (Mountari, 2013) included 8 clinical cases diagnosed with lymphoma 
(cutaneous, malignant, leukemia), where sTK1 activity was measured by the same assay as in this study. 
Three of these cases had sTK1 activity values <0.933 pmol/min/mL (0.83, 0.84 and 0.85), but the other 
five cats had values >0.933 pmol/min/mL (1.15, 1.22, 1.25, 3.75 and 7.44). This implies that the sTK1 
activity is not suitable to be the single tool in the diagnosis making, as three of these lymphoma cats 
would have been missed based on only sTK1 activity using the suggested reference value. However, 5 
of the 8 cats were above the calculated reference value. Moreover all of the 8 lymphoma cats were above 
the reference group’s median and mean values. This is of course not a statistical proposition but it might 
be seen as a positive trend that suggests further studies on this topic. It would also be interesting to study 
diagnosed lymphoma cats that were to be followed during treatment and to see whether the sTK1 activity 
could function as a monitoring test to evaluate the treatment. 
A strength of this study was that the cats included had to be both clinically healthy and healthy on blood 
screening, thus using a subjective as well as an objective factor in the inclusion criteria, i.e. the cats 
included in this study were well examined and it can be assumed that the cats were truly healthy. Another 
strength is that sTK1 stability is known to be maintained in various temperatures etc. thus assuming that 
storage of the samples did not affect the results (Taylor et al., 2013). 
In this master thesis, the sTK1 activity was measured. A study that was performed in 2013 analyzed 
both sTK1 activity and sTK1 protein levels in healthy dogs and in dogs with lymphoma, concluded that 
the actual sTK1 protein levels were of greater clinical value, especially for solid tumors (Kiran Kumar 
et al., 2013). This would be interesting to study in feline patients as well. 
This study serves as a baseline for future studies. For example, it would be of great use to compare sTK1 
activity levels in cats diagnosed with lymphoma. As shown here, there seems to be no specific individual 
variation in the sTK1 activity, meaning that the whole study group and the results can be used to make 
comparisons and statistical analysis based on results from cats diagnosed with lymphoma.  
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CONCLUSION 
The reference value for sTK1 activity in healthy cats is, according to this study, <0.933 pmol/min/mL. 
The results also showed that there is no individual variation in sTK1 activity, i.e. there is no significant 
difference between males and females or between cats 1 years old and cats 2 years old. 
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